← Back to Search

Survivorship Care Planning + Telehealth Education for Cancer

N/A
Waitlist Available
Led By Eric Chow
Research Sponsored by Fred Hutchinson Cancer Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History of either adult-onset (age >= 18) lymphoma, breast, colorectal, lung, or prostate cancer
Be older than 18 years old
Must not have
Currently on palliative or hospice care, or considering transferring to such care within the next 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how well self-generated survivorship care plans and telehealth education work in improving knowledge and self-efficacy in cancer survivors living in rural areas.

Who is the study for?
This trial is for adult cancer survivors who finished curative therapy within the last 5 years and have a history of lymphoma, breast, colorectal, lung, or prostate cancer. They must be able to do study tasks like questionnaires and agree to randomization. Participants need access to a phone and can receive materials electronically. It excludes those on palliative care or without telephone access.
What is being tested?
The IMPACT Study tests if self-generated survivorship care plans combined with telehealth education improve knowledge and self-efficacy in rural cancer survivors. The goal is better transition from oncology to primary care and improved communication between healthcare providers.
What are the potential side effects?
Since this trial involves educational interventions rather than medical treatments, traditional side effects are not applicable. However, participants may experience stress or discomfort when discussing their cancer experiences.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had cancer (lymphoma, breast, colorectal, lung, or prostate) as an adult.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am receiving or considering palliative or hospice care soon.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Accuracy of survivors' self-generated survivorship care plans (SCPs) in relation to those based on medical record abstraction
Secondary study objectives
Local oncology clinics' attitudes towards survivorship care implementation
PCP self-efficacy towards survivorship care
Participant perceived self-efficacy: questionnaire using the PROMIS Global 10 and health related self-efficacy scales
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (patient-generated SCP, educational counseling)Experimental Treatment3 Interventions
Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
Group II: Arm I (patient-generated SCP)Active Control2 Interventions
Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor
443 Previous Clinical Trials
147,794 Total Patients Enrolled
93 Trials studying Lymphoma
5,782 Patients Enrolled for Lymphoma
Fred Hutchinson Cancer CenterLead Sponsor
569 Previous Clinical Trials
1,341,929 Total Patients Enrolled
100 Trials studying Lymphoma
6,162 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,907 Previous Clinical Trials
41,011,944 Total Patients Enrolled
1,405 Trials studying Lymphoma
382,744 Patients Enrolled for Lymphoma
~22 spots leftby Jun 2025